JP2014502276A5 - - Google Patents

Download PDF

Info

Publication number
JP2014502276A5
JP2014502276A5 JP2013542218A JP2013542218A JP2014502276A5 JP 2014502276 A5 JP2014502276 A5 JP 2014502276A5 JP 2013542218 A JP2013542218 A JP 2013542218A JP 2013542218 A JP2013542218 A JP 2013542218A JP 2014502276 A5 JP2014502276 A5 JP 2014502276A5
Authority
JP
Japan
Prior art keywords
seq
antibody
apoe
amino acid
medicament
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013542218A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014502276A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/063121 external-priority patent/WO2012075422A2/en
Publication of JP2014502276A publication Critical patent/JP2014502276A/ja
Publication of JP2014502276A5 publication Critical patent/JP2014502276A5/ja
Pending legal-status Critical Current

Links

JP2013542218A 2010-12-02 2011-12-02 アミロイドプラーク関連症状の治療のための組成物及び方法 Pending JP2014502276A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US41906010P 2010-12-02 2010-12-02
US61/419,060 2010-12-02
US201161548542P 2011-10-18 2011-10-18
US61/548,542 2011-10-18
PCT/US2011/063121 WO2012075422A2 (en) 2010-12-02 2011-12-02 Compositions and methods for treating amyloid plaque associated symptoms

Publications (2)

Publication Number Publication Date
JP2014502276A JP2014502276A (ja) 2014-01-30
JP2014502276A5 true JP2014502276A5 (2) 2015-01-22

Family

ID=46172597

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013542218A Pending JP2014502276A (ja) 2010-12-02 2011-12-02 アミロイドプラーク関連症状の治療のための組成物及び方法

Country Status (14)

Country Link
US (2) US20140037638A1 (2)
EP (1) EP2646053A4 (2)
JP (1) JP2014502276A (2)
KR (1) KR20140017513A (2)
CN (1) CN103338786A (2)
AU (1) AU2011336360A1 (2)
BR (1) BR112013013723A2 (2)
CA (1) CA2819679A1 (2)
MX (1) MX2013006116A (2)
NZ (1) NZ611614A (2)
RU (1) RU2013130002A (2)
SG (1) SG190952A1 (2)
WO (1) WO2012075422A2 (2)
ZA (1) ZA201303996B (2)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2847218A4 (en) * 2012-05-08 2015-12-30 Univ Ramot APOE4 ANTIBODY FOR THE TREATMENT OF NEURODEEGENERATIVE DISEASES
WO2016054247A1 (en) 2014-09-30 2016-04-07 Washington University Tau kinetic measurements
EP3452074A4 (en) * 2016-05-03 2019-12-11 University of South Florida COMPOSITIONS AND METHOD FOR MODULATING THE ABETA PROTEIN
CA3042236A1 (en) 2016-10-28 2018-05-03 Washington University Anti-apoe antibodies
EP3655026A4 (en) 2017-07-17 2021-07-28 Janssen Biotech, Inc. ANTIGBINDING REGIONS AGAINST FIBRONECTIN TYPE III DOMAINS AND METHOD OF USING THEREOF
AU2020282792B2 (en) * 2019-05-28 2025-12-04 Banner Health ApoE antibodies, fusion proteins and uses thereof
US20240400659A1 (en) * 2021-10-19 2024-12-05 Bioatla, Inc. Conditionally active proteins for neurodegenerative diseases
JP2025540077A (ja) * 2022-11-30 2025-12-11 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ ナチュラルキラー細胞エンゲージャー
WO2026019667A1 (en) * 2024-07-17 2026-01-22 Jn Biosciences Llc Trispecific antibodies for activation of immune cells

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3265577B2 (ja) * 1992-10-13 2002-03-11 デューク・ユニバーシティ アポリポ蛋白eの4型イソ型の測定法
RU2006122946A (ru) * 2003-11-28 2008-01-10 Астразенека Аб (Se) Антитела
EP1736162A1 (en) * 2004-03-30 2006-12-27 Renomedix Institute Inc. Remedy for prion disease and method of producing the same
US20070248599A1 (en) * 2006-02-21 2007-10-25 Jordan Tang Treatment of alzheimer's disease with inhibitors of apoe binding to apoe receptor
CA2672581A1 (en) * 2006-12-14 2008-06-19 Forerunner Pharma Research Co., Ltd. Anti-claudin 3 monoclonal antibody and treatment and diagnosis of cancer using the same
CL2008002775A1 (es) * 2007-09-17 2008-11-07 Amgen Inc Uso de un agente de unión a esclerostina para inhibir la resorción ósea.
EP2542581A4 (en) * 2010-03-01 2014-01-22 David Gladstone Inst APOLIPOPROTEIN-SPECIFIC ANTIBODY AND METHOD OF USE THEREOF

Similar Documents

Publication Publication Date Title
JP2014502276A5 (2)
JP2009530423A5 (2)
US11926660B2 (en) Anti-ApoE antibodies
JP2015530971A5 (2)
Antonios et al. Alzheimer therapy with an antibody against N-terminal Abeta 4-X and pyroglutamate Abeta 3-X
RU2013130002A (ru) Композиции и способы лечения симптомов, ассоциированных с амилоидными бляшками
MX2009013503A (es) Anticuerpo monoclonal anti-amiloide-beta.
JP2010506596A5 (2)
JP2010526028A5 (2)
IL261019A (en) Antibodies to 6 -il and their use
JP2019527194A5 (2)
WO2010012004A3 (en) Monoclonal antibodies specific for pathological amyoid aggregates common to amyloids formed from proteins of differing sequence
JP2015533795A5 (2)
JP2022541539A5 (2)
JP2020517740A5 (2)
IL275720B (en) Use of molecules that bind semphorin-d4 for the treatment of neurodegenerative disorders
RU2008137764A (ru) Способы предотвращения и лечения амилоидных заболеваний
JP2017536102A5 (2)
WO2008060364A3 (en) Humani zed antibody against amyloid beta
JP2013538796A5 (2)
JP2018505651A5 (2)
JP2012504634A5 (2)
JP2014509510A5 (2)
JP2010507594A5 (2)
JP2019522961A5 (2)